Skip to main content
Erschienen in: Endocrine Pathology 1/2013

01.03.2013

mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features

verfasst von: Emir Ahmed Sajjad, Grzegorz Zieliński, Maria Maksymowicz, Łukasz Hutnik, Tomasz Bednarczuk, Paweł Włodarski

Erschienen in: Endocrine Pathology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Initiating factors and mechanisms of tumor formation are poorly understood in nonfamilial pituitary adenomas. Alteration of intracellular pathways is an underlying event in numerous neoplasms. Among them, excessive activation of mammalian target of rapamycin (mTOR) pathway and its two main regulators, Akt and Erk, has been detected frequently in solid tumors. This study tests the activation of mTOR pathway in pituitary adenomas and its influence on their morphopathological features. Fifty-three pituitary adenomas were fresh frozen after surgery and analyzed by western blotting using phospho-specific antibodies. The impact of Akt and Erk activation on mTOR pathway was assessed in five primary cultures derived from the excised adenomas using selective kinase inhibitors. Statistical correlations of size, volume, Ki-67 %, Knosp’s grading, and somatostatin receptor (SSTR) expression with the activation of mentioned kinases was performed. GHomas showed the highest frequency (71 %) and level of mTOR pathway activity comparing to other adenomas (33 %). No significant correlation was found between mTOR activation and any of the morphopathological features in the studied samples. mTOR kinase phosphorylation was independent of Erk and Akt in primary cultures. Erk activity was significant in all types of adenomas but was the highest in control samples. Its phosphorylation correlated inversely with the Knosp’s grading in nonfunctional pituitary adenomas and directly with somatostatin receptor subtype 2 A expression in GHomas. Presented data point to the noteworthy mTOR activity in GHomas. However, the lack of correlation with morphopathological features, its independence of Erk and Akt phosphorylation, and high level of Erk activity in control pituitary necessitate further research for clarifying the role of these pathways in pituitary adenomas.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Salehi F, Kovacs K, Scheithauer BW, Cantelmi D, Horvath E, Lloyd RV, Cusimano M (2010) Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. Int J Surg Pathol 18 (1):5–13. doi:10.1177/1066896909356105 PubMedCrossRef Salehi F, Kovacs K, Scheithauer BW, Cantelmi D, Horvath E, Lloyd RV, Cusimano M (2010) Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. Int J Surg Pathol 18 (1):5–13. doi:10.​1177/​1066896909356105​ PubMedCrossRef
3.
Zurück zum Zitat Lloyd RJ, Kovacs K, Young WFJ, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, Watson REJ, Lindell EP, Barkan AL, Saeger W, Nose´ V, Osamura RY, Ezzat S, Yamada S, Roncaroli F, Lopes MBS, Vidal Ruibal S (2004) Tumours of the pituitary in WHO Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs. International Agency for Research and Cancer (IARC):9–48 Lloyd RJ, Kovacs K, Young WFJ, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, Watson REJ, Lindell EP, Barkan AL, Saeger W, Nose´ V, Osamura RY, Ezzat S, Yamada S, Roncaroli F, Lopes MBS, Vidal Ruibal S (2004) Tumours of the pituitary in WHO Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs. International Agency for Research and Cancer (IARC):9–48
5.
Zurück zum Zitat Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER, Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38 (1):99–106; discussion 106–107PubMedCrossRef Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER, Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38 (1):99–106; discussion 106–107PubMedCrossRef
9.
Zurück zum Zitat Horvath A, Stratakis CA (2008) Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord 9 (1):1–11. doi:10.1007/s11154-007-9066-9 PubMedCrossRef Horvath A, Stratakis CA (2008) Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord 9 (1):1–11. doi:10.​1007/​s11154-007-9066-9 PubMedCrossRef
13.
Zurück zum Zitat Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16 (4):1329–1338. doi:10.1677/ERC-09-0101 PubMedCrossRef Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16 (4):1329–1338. doi:10.​1677/​ERC-09-0101 PubMedCrossRef
14.
Zurück zum Zitat Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M, Coculescu M, Basu S, Grossman AB (2005) Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 12 (2):423–433. doi:10.1677/erc.1.00949 PubMedCrossRef Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M, Coculescu M, Basu S, Grossman AB (2005) Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 12 (2):423–433. doi:10.​1677/​erc.​1.​00949 PubMedCrossRef
15.
Zurück zum Zitat Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak S, Hanzely Z, Kola B, Korbonits M, Grossman AB (2007) A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66 (3):348–352. doi:10.1111/j.1365-2265.2006.02735.x CrossRef Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak S, Hanzely Z, Kola B, Korbonits M, Grossman AB (2007) A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 66 (3):348–352. doi:10.​1111/​j.​1365-2265.​2006.​02735.​x CrossRef
20.
21.
Zurück zum Zitat Kim SH, Zukowski K, Novak RF (2009) Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Res 29 (4):1143–1150. doi:29/4/1143 PubMed Kim SH, Zukowski K, Novak RF (2009) Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Res 29 (4):1143–1150. doi:29/​4/​1143 PubMed
22.
Zurück zum Zitat Dieterlen MT, Bittner HB, Klein S, von Salisch S, Mittag A, Tarnok A, Dhein S, Mohr FW, Barten MJ (2011) Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry B Clin Cytom. doi:10.1002/cyto.b.21005 Dieterlen MT, Bittner HB, Klein S, von Salisch S, Mittag A, Tarnok A, Dhein S, Mohr FW, Barten MJ (2011) Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry B Clin Cytom. doi:10.​1002/​cyto.​b.​21005
23.
Zurück zum Zitat O’Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I (2009) Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 15 (8):2872–2878. doi:10.1158/1078-0432.CCR-08-2336 PubMedCrossRef O’Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I (2009) Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 15 (8):2872–2878. doi:10.​1158/​1078-0432.​CCR-08-2336 PubMedCrossRef
24.
Zurück zum Zitat Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP (2009) Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 132 (Pt 6):1509–1522. doi:10.1093/brain/awp093 PubMedCrossRef Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP (2009) Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 132 (Pt 6):1509–1522. doi:10.​1093/​brain/​awp093 PubMedCrossRef
25.
Zurück zum Zitat Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11(7): 36–42 Abramoff MD, Magalhaes PJ, Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11(7): 36–42
26.
Zurück zum Zitat Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA (2005) Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65 (17):7800–7808. doi:10.1158/0008-5472.CAN-04-4180 PubMed Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, Wasik MA (2005) Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65 (17):7800–7808. doi:10.​1158/​0008-5472.​CAN-04-4180 PubMed
27.
Zurück zum Zitat Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 (4):610–617; discussion 617–618PubMedCrossRef Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33 (4):610–617; discussion 617–618PubMedCrossRef
29.
Zurück zum Zitat Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (6):514–523. doi:10.1056/NEJMoa1009290 PubMedCrossRef Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (6):514–523. doi:10.​1056/​NEJMoa1009290 PubMedCrossRef
30.
Zurück zum Zitat Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95 (2):968–976. doi:10.1210/jc.2009-1641 PubMedCrossRef Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95 (2):968–976. doi:10.​1210/​jc.​2009-1641 PubMedCrossRef
31.
Zurück zum Zitat Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 70 (2):666–674. doi:10.1158/0008-5472.CAN-09-2951 PubMedCrossRef Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 70 (2):666–674. doi:10.​1158/​0008-5472.​CAN-09-2951 PubMedCrossRef
32.
Zurück zum Zitat Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16 (3):1017–1027. doi:10.1677/ERC-08-0269 PubMedCrossRef Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16 (3):1017–1027. doi:10.​1677/​ERC-08-0269 PubMedCrossRef
33.
Zurück zum Zitat Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4 (8):556–564. doi:10.1038/ncb822 ncb822PubMed Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4 (8):556–564. doi:10.​1038/​ncb822 ncb822PubMed
36.
37.
Zurück zum Zitat Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen J, Terezakis S, Kleinberg L, Redmond K, Hales RK, Salvatori R, Quinones-Hinojosa A, Tran PT, Lim M (2011) Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol Ther 12 (7):657–663. doi:17172 PubMedCrossRef Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen J, Terezakis S, Kleinberg L, Redmond K, Hales RK, Salvatori R, Quinones-Hinojosa A, Tran PT, Lim M (2011) Nelfinavir induces radiation sensitization in pituitary adenoma cells. Cancer Biol Ther 12 (7):657–663. doi:17172 PubMedCrossRef
38.
Zurück zum Zitat Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G (2012) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15 (1):37–43. doi:10.1007/s11102-011-0341-0 PubMedCrossRef Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G (2012) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15 (1):37–43. doi:10.​1007/​s11102-011-0341-0 PubMedCrossRef
Metadaten
Titel
mTOR is Frequently Active in GH-Secreting Pituitary Adenomas without Influencing their Morphopathological Features
verfasst von
Emir Ahmed Sajjad
Grzegorz Zieliński
Maria Maksymowicz
Łukasz Hutnik
Tomasz Bednarczuk
Paweł Włodarski
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 1/2013
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9230-y

Weitere Artikel der Ausgabe 1/2013

Endocrine Pathology 1/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie